TrialJournal of clinical immunology2016

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Richard L Wasserman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.